55.61
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché NVO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$56.04
Aprire:
$55.6
Volume 24 ore:
17.69M
Relative Volume:
1.08
Capitalizzazione di mercato:
$188.53B
Reddito:
$45.44B
Utile/perdita netta:
$16.18B
Rapporto P/E:
15.30
EPS:
3.634
Flusso di cassa netto:
$9.21B
1 W Prestazione:
-9.43%
1M Prestazione:
+0.49%
6M Prestazione:
-22.47%
1 anno Prestazione:
-55.26%
Novo Nordisk Adr Stock (NVO) Company Profile
Nome
Novo Nordisk Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta NVO con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
NVO
Novo Nordisk Adr
|
55.61 | 249.01B | 45.44B | 16.18B | 9.21B | 3.634 |
![]()
LLY
Lilly Eli Co
|
724.54 | 640.60B | 53.26B | 13.80B | -50.20M | 15.30 |
![]()
JNJ
Johnson Johnson
|
179.71 | 428.03B | 90.62B | 22.66B | 18.18B | 9.35 |
![]()
ABBV
Abbvie Inc
|
220.61 | 386.06B | 58.33B | 3.73B | 18.24B | 2.10 |
![]()
NVS
Novartis Ag Adr
|
123.65 | 236.62B | 53.40B | 13.68B | 16.89B | 6.9231 |
![]()
MRK
Merck Co Inc
|
78.56 | 193.83B | 63.43B | 16.42B | 14.72B | 6.49 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
2025-09-16 | Aggiornamento | Rothschild & Co Redburn | Neutral → Buy |
2025-09-09 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
2025-08-13 | Aggiornamento | BNP Paribas Exane | Underperform → Neutral |
2025-08-05 | Downgrade | UBS | Buy → Neutral |
2025-07-31 | Downgrade | HSBC Securities | Buy → Hold |
2025-07-30 | Downgrade | Barclays | Overweight → Equal Weight |
2025-04-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
2025-03-13 | Aggiornamento | Kepler | Hold → Buy |
2025-03-03 | Downgrade | Stifel | Buy → Hold |
2025-02-12 | Iniziato | Morgan Stanley | Equal-Weight |
2025-01-06 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
2024-05-30 | Iniziato | Goldman | Buy |
2024-04-12 | Iniziato | BMO Capital Markets | Outperform |
2024-01-23 | Iniziato | Morgan Stanley | Overweight |
2024-01-16 | Ripresa | UBS | Neutral |
2023-12-01 | Iniziato | Cantor Fitzgerald | Overweight |
2023-10-02 | Iniziato | Argus | Buy |
2023-07-14 | Iniziato | HSBC Securities | Buy |
2022-07-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2022-06-28 | Downgrade | UBS | Neutral → Sell |
2022-06-27 | Aggiornamento | Exane BNP Paribas | Underperform → Neutral |
2022-06-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
2022-05-31 | Aggiornamento | Guggenheim | Neutral → Buy |
2022-04-25 | Aggiornamento | Cowen | Market Perform → Outperform |
2022-04-12 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
2022-03-16 | Aggiornamento | Deutsche Bank | Hold → Buy |
2022-01-25 | Downgrade | Liberum | Hold → Sell |
2021-12-20 | Downgrade | JP Morgan | Overweight → Neutral |
2021-12-17 | Downgrade | Deutsche Bank | Buy → Hold |
2021-01-20 | Downgrade | Credit Suisse | Outperform → Neutral |
2021-01-15 | Iniziato | Deutsche Bank | Buy |
2020-09-29 | Iniziato | Berenberg | Hold |
2020-07-06 | Downgrade | BofA Securities | Buy → Neutral |
2020-05-11 | Downgrade | UBS | Buy → Neutral |
2020-05-04 | Iniziato | Cowen | Market Perform |
2020-03-16 | Aggiornamento | BofA/Merrill | Neutral → Buy |
2020-01-03 | Downgrade | Guggenheim | Buy → Neutral |
2019-11-18 | Aggiornamento | Barclays | Equal Weight → Overweight |
2019-09-17 | Aggiornamento | Citigroup | Neutral → Buy |
2019-08-30 | Downgrade | Jefferies | Hold → Underperform |
2019-06-20 | Downgrade | Deutsche Bank | Buy → Hold |
2019-06-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
2019-04-29 | Aggiornamento | Credit Suisse | Neutral → Outperform |
2019-01-29 | Iniziato | Exane BNP Paribas | Outperform |
2018-12-11 | Ripresa | Jefferies | Hold |
2018-10-09 | Iniziato | Guggenheim | Buy |
2017-12-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
2017-12-06 | Aggiornamento | BofA/Merrill | Neutral → Buy |
2017-12-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2017-09-25 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
2017-09-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
Mostra tutto
Novo Nordisk Adr Borsa (NVO) Ultime notizie
Novo Nordisk ADR earnings missed, revenue topped estimates By Investing.com - Investing.com Nigeria
Is Pfizer Stock a Buy After Its $5 Billion GLP-1 Bet? - The Motley Fool
Novo Nordisk ADR earnings missed, revenue topped estimates - Investing.com India
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming DeadlinesNVO | FinancialContent - FinancialContent
NVO Stock Quote Price and Forecast - CNN
NVO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important September 30 Deadline in Securities Class Action - GlobeNewswire Inc.
NVO IMPORTANT DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors with Losses in Excess of $100K to Secure Counsel Before Important September 30 Deadline in Securities Class Action - GlobeNewswire Inc.
Tools to assess Novo Nordisk A s (b Shares) Adrhedged’s risk profileJuly 2025 Setups & Technical Pattern Based Buy Signals - newser.com
Novo Nordisk And Prudential Stand Out In European ADR Gains - Finimize
Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs - Sahm
Custom strategy builders for tracking Novo Nordisk A s (b Shares) AdrhedgedStock Surge & AI Forecasted Entry/Exit Points - newser.com
Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study - Sahm
How Do Investors Really Feel About Novo Nordisk? - Sahm
NVO DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important September 30 Deadline in Securities Class Action - GlobeNewswire Inc.
Live market analysis of Novo Nordisk A s (b Shares) AdrhedgedInsider Buying & Comprehensive Market Scan Insights - newser.com
Published on: 2025-09-17 04:52:55 - newser.com
Advanced analytics toolkit walkthrough for Novo Nordisk A s (b Shares) AdrhedgedGap Down & AI Powered Trade Plan Recommendations - newser.com
Price momentum metrics for Novo Nordisk A s (b Shares) Adrhedged explainedMarket Growth Review & AI Driven Price Forecasts - newser.com
Aug Highlights: Is Novo Nordisk A s (b Shares) Adrhedged forming a bullish divergenceWeekly Investment Report & Entry Point Confirmation Alerts - khodrobank.com
Targets Report: Is Novo Nordisk A s b Shares Adrhedged stock heavily shorted2025 Pullback Review & Fast Entry Momentum Alerts - خودرو بانک
Risk Report: Can Novo Nordisk A s b Shares Adrhedged be the next market leaderWeekly Trade Review & Technical Buy Zone Confirmation - خودرو بانک
What's Going On With Novo Nordisk Shares Monday? - Sahm
ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Is the Market Bullish or Bearish on Novo Nordisk? - Sahm
Faruqi & Faruqi Reminds Novo Nordisk Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 30, 2025 - GlobeNewswire Inc.
Emmy Award Success for Passion and Robert Valleys 400 Boys Episode in Netflixs Love, Death and Robots - DLH.net
Novo Nordisk To Cut 9,000 Jobs As Competition From Eli Lilly Heats Up: Analyst Calls Move 'Tough, Natural...Very Necessary' - Sahm
Teva Pharmaceutical ADR Trying To Close In On Key Technical Measure - Investor's Business Daily
NOVO_B Stock Price and Chart — OMXCOP:NOVO_B - TradingView
ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Novo Nordisk Adr Azioni (NVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):